<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00311545</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000462096</org_study_id>
    <secondary_id>S0351</secondary_id>
    <secondary_id>U10CA032102</secondary_id>
    <nct_id>NCT00311545</nct_id>
  </id_info>
  <brief_title>S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer</brief_title>
  <official_title>A Phase II Study of CNTO 328, A Monoclonal Antibody Against Interleukin-6 (IL-6), In Patients With Advanced or Metastatic Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southwest Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Southwest Oncology Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways.&#xD;
      Some block the ability of tumor cells to grow and spread. Others find tumor cells and help&#xD;
      kill them or carry tumor-killing substances to them.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well CNTO 328 works in treating patients with&#xD;
      unresectable or metastatic kidney cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Assess the probability of response (confirmed complete and partial responses) in&#xD;
           patients with unresectable or metastatic renal cell cancer treated with CNTO 328.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Assess the 6-month progression-free survival probability and median overall survival in&#xD;
           these patients.&#xD;
&#xD;
        -  Evaluate the qualitative and quantitative toxicities of this treatment.&#xD;
&#xD;
        -  Investigate, in a preliminary manner, the association of tumor response with potential&#xD;
           markers of anti-interleukin-6 activity.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive CNTO 328 IV over 2 hours on day 1. Treatment repeats every 2 weeks for 6&#xD;
      courses in the absence of disease progression or unacceptable toxicity. Patients achieving&#xD;
      complete or partial response after 6 courses of therapy may receive an additional 6 courses.&#xD;
&#xD;
      After completion of study treatment, patients are followed periodically for 3 years.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    withdrawal of support for drug supply&#xD;
  </why_stopped>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Kidney Cancer</condition>
  <arm_group>
    <arm_group_label>CNTO 328</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CNTO 328, anti-IL-6 monoclonal antibody; 6 mg/kg, IV, q 2wks x 12 cycles (1 cycle = 2 wks)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CNTO 328</intervention_name>
    <description>Anti-IL-6 chimeric monoclonal antibody</description>
    <arm_group_label>CNTO 328</arm_group_label>
    <other_name>Siltuximab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic or unresectable primary renal&#xD;
             cell carcinoma&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  Soft tissue disease within a prior radiation field may be considered measurable&#xD;
                  disease provided all of the following are true:&#xD;
&#xD;
                    -  Patient also has measurable disease outside of the irradiated field&#xD;
&#xD;
                    -  Disease within the irradiated field has progressed since prior radiotherapy&#xD;
&#xD;
                    -  Radiotherapy was completed more than 2 months ago&#xD;
&#xD;
          -  Ineligible for high-dose interleukin-2&#xD;
&#xD;
          -  No treated or untreated brain metastases&#xD;
&#xD;
               -  No history of brain metastases&#xD;
&#xD;
               -  Patients with clinical evidence of brain metastases must have brain CT scan or&#xD;
                  MRI negative for metastatic disease within 56 days prior to study entry&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Zubrod performance status 0-2&#xD;
&#xD;
          -  Absolute granulocyte count ≥ 1,500/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Bilirubin ≤ 3 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT ≤ 3 times ULN&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No more than 2 of the following:&#xD;
&#xD;
               -  Zubrod PS 2&#xD;
&#xD;
               -  Lactate dehydrogenase &gt; 1.5 times ULN&#xD;
&#xD;
               -  Hemoglobin &lt; lower limit of normal&#xD;
&#xD;
               -  Calcium &gt; 10 mg/dL&#xD;
&#xD;
               -  Absence of prior nephrectomy&#xD;
&#xD;
          -  No uncontrolled intercurrent illness, including any of the following:&#xD;
&#xD;
               -  Uncontrolled diabetes mellitus&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Psychiatric illness or social situation that would limit compliance with study&#xD;
                  requirements&#xD;
&#xD;
          -  No HIV positivity&#xD;
&#xD;
          -  No other prior malignancy, excluding the following:&#xD;
&#xD;
               -  Adequately treated basal cell or squamous cell skin cancer&#xD;
&#xD;
               -  In situ cervical cancer&#xD;
&#xD;
               -  Adequately treated stage I or II cancer for which the patient is currently in&#xD;
                  complete remission&#xD;
&#xD;
               -  Any other cancer for which the patient has been disease free for 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 28 days since prior tumor resection and recovered&#xD;
&#xD;
          -  No prior immunotherapy or chemotherapy regimens with interferon (IFN) and/or&#xD;
             interleukin-2 (IL-2) or the combination of IFN/IL-2&#xD;
&#xD;
          -  No prior cytotoxic chemotherapy for renal cell cancer&#xD;
&#xD;
          -  No prior murine or chimeric proteins or human/murine recombination products (i.e.,&#xD;
             other chimeric monoclonal antibodies)&#xD;
&#xD;
          -  No concurrent radiotherapy or systemic therapy for renal cell cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacek K. Pinski, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Philip C. Mack, Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>UC Davis Cancer Center</affiliation>
  </overall_official>
  <verification_date>February 2013</verification_date>
  <study_first_submitted>April 5, 2006</study_first_submitted>
  <study_first_submitted_qc>April 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 6, 2006</study_first_posted>
  <last_update_submitted>February 19, 2013</last_update_submitted>
  <last_update_submitted_qc>February 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>recurrent renal cell cancer</keyword>
  <keyword>stage IV renal cell cancer</keyword>
  <keyword>stage III renal cell cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Siltuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

